Background NCI launched the C3I to support the implementation of tobacco treatment programs at NCI-designated Cancer Centers nationwide. 1 C3I has a specific objective “to help cancer centers build and implement sustainable tobacco cessation
Search Results
Sustainability of Tobacco Treatment Programs in the Cancer Center Cessation Initiative
The Cancer Center Cessation Initiative Sustainability Working Group
Clinical Assessment of Breast Cancer Risk Based on Family History
Kaylene Ready and Banu Arun
B reast cancer is the most common cancer among women in the United States with a lifetime risk of 1 in 8 (12%). 1 Multiple risk factors for breast cancer have been identified and include gender, age, race, benign breast disease (atypical ductal
Colorectal Cancer Screening
Randall W. Burt, Jamie A. Cannon, Donald S. David, Dayna S. Early, James M. Ford, Francis M. Giardiello, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Kory Jasperson, Jason B. Klapman, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman, David Weinberg, Mary Dwyer, and Deborah Freedman-Cass
appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Overview
Ethical Obligations and Counseling Challenges in Cancer Genetics
Wylie Burke and Nancy Press
Supported in part by grant HG02263 from the National Institutes of Health. References 1. Queller J . Cancer and the maiden . NY Times National Edition , Mar 5 , 2005 . 2. Crawshaw R Rogers DE Pellegrino ED
Point: TheValue of Predicting Life Expectancy in Men with Clinically Localized Prostate Cancer
Douglass B. Clayton and Donald A. Urban
The authors have no financial interest, arrangement, or affiliation with the manufacturers of any products discussed in the article or their competitors. References 1. Weeks JC Cook EF O'Day SJ . Relationship of cancer patient
A Cancer-Related Fatigue Clinic: Opportunities and Challenges
Carmen P. Escalante, Ellen Manzullo, and Rosalie Valdres
The authors receive grant funding from Ortho Biotech Oncology. References 1 Mock V Atkinson A Barsevick A NCCN cancer-related fatigue clinical practice guidelines in oncology . Oncology 2000 ; 14 : 151 – 161 . 2
Mental Illness Stigma as a Barrier to Psychosocial Services for Cancer Patients
Alicia K. Matthews, Patrick W. Corrigan, and Judith Lee Rutherford
of cancer, 1973-1998; feature focuses on cancers with recent increasing trends . J Natl Cancer Inst 93 : 824 – 842 . 2 Ries LG Wingo PA Miller DS . The annual report to the nation on the status of cancer, 1973-1997, with a special
Representation of Sexual and Gender Minority People in Patient Nondiscrimination Policies of Cancer Centers in the United States
Iman K. Berrahou, Ava Snow, Megan Swanson, and Juno Obedin-Maliver
million LGBTQ cancer survivors living in the United States. 1 , 2 Although it is known that SGM people get cancer, the incidence and prevalence of cancer in this population remain unknown, because no national health surveys or cancer registries routinely
Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical Trials
Matthew Perez, Caitlin C. Murphy, Sandi L. Pruitt, Sawsan Rashdan, Asal Rahimi, and David E. Gerber
Background In December 2021, NCI issued revised guidance on eligibility criteria for cancer clinical trials. 1 Based on 2017/2021 recommendations from ASCO and Friends of Cancer Research (Friends), 2 – 4 the document addresses several
Rectal Cancer
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Lucille A. Leong, Edward Lin, Michael G. Martin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Deborah A. Freedman-Cass, and Kristina M. Gregory
appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Overview
